Welcome, PharmD students, to this focused MCQ quiz on Cost-Minimization Analysis (CMA) and Cost-Effectiveness Analysis (CEA)! These are two fundamental types of pharmacoeconomic evaluations used to compare the value of different health interventions. Understanding when and how to apply CMA and CEA, how to interpret their results (like the ICER for CEA), and their respective limitations is crucial for making informed decisions about resource allocation in healthcare. This quiz will test your knowledge of these important analytical tools. Let’s begin!
1. Cost-Minimization Analysis (CMA) is the most appropriate pharmacoeconomic method when:
- a) Two or more interventions have different therapeutic outcomes.
- b) The therapeutic outcomes of two or more interventions are demonstrated or assumed to be equivalent.
- c) The benefits of interventions are measured in monetary terms.
- d) Outcomes are measured in Quality-Adjusted Life Years (QALYs).
Answer: b) The therapeutic outcomes of two or more interventions are demonstrated or assumed to be equivalent.
2. The primary objective of a Cost-Minimization Analysis (CMA) is to:
- a) Determine the most effective intervention regardless of cost.
- b) Identify the intervention with the highest benefit-to-cost ratio.
- c) Choose the least costly intervention among those with equivalent clinical outcomes.
- d) Calculate the cost per QALY gained.
Answer: c) Choose the least costly intervention among those with equivalent clinical outcomes.
3. Which of the following is a critical prerequisite for conducting a valid Cost-Minimization Analysis?
- a) Strong evidence from clinical trials or literature demonstrating therapeutic equivalence between the comparators.
- b) The interventions must have different mechanisms of action.
- c) One intervention must be significantly more expensive than the other.
- d) The study must be conducted from a societal perspective.
Answer: a) Strong evidence from clinical trials or literature demonstrating therapeutic equivalence between the comparators.
4. In a Cost-Effectiveness Analysis (CEA), health outcomes are typically measured in:
- a) Monetary units only.
- b) Natural health units, such as life-years gained, cases cured, or blood pressure reduction.
- c) Utility values ranging from 0 to 1.
- d) Patient satisfaction scores only.
Answer: b) Natural health units, such as life-years gained, cases cured, or blood pressure reduction.
5. The result of a Cost-Effectiveness Analysis comparing two alternatives is often expressed as a(n):
- a) Benefit-to-cost ratio.
- b) Net monetary benefit.
- c) Incremental Cost-Effectiveness Ratio (ICER).
- d) Return on investment.
Answer: c) Incremental Cost-Effectiveness Ratio (ICER).
6. The Incremental Cost-Effectiveness Ratio (ICER) is calculated as:
- a) (Cost of Intervention A) / (Effectiveness of Intervention A)
- b) (Difference in Costs between A and B) / (Difference in Effectiveness between A and B)
- c) (Total Effectiveness) / (Total Cost)
- d) (Difference in QALYs) / (Difference in Costs)
Answer: b) (Difference in Costs between A and B) / (Difference in Effectiveness between A and B)
7. If a new drug (Drug X) costs $500 more than the standard drug (Drug Y) and provides an additional 0.5 life-years gained, the ICER for Drug X compared to Drug Y is:
- a) $250 per life-year gained.
- b) $500 per life-year gained.
- c) $1000 per life-year gained.
- d) $0.001 per life-year gained.
Answer: c) $1000 per life-year gained. (ICER = $500 / 0.5 LYS)
8. A Cost-Effectiveness Analysis is most useful when comparing interventions that:
- a) Have identical outcomes but different costs.
- b) Have different costs and different levels of effectiveness, where effectiveness is measured in the same natural unit.
- c) Can have their benefits easily converted into monetary terms.
- d) Are both less effective than doing nothing.
Answer: b) Have different costs and different levels of effectiveness, where effectiveness is measured in the same natural unit.
9. A key limitation of Cost-Effectiveness Analysis (CEA) is that it:
- a) Cannot compare interventions with different types of outcomes (e.g., cannot directly compare an intervention that reduces blood pressure with one that prevents fractures, unless a common outcome is found).
- b) Always requires outcomes to be measured in QALYs.
- c) Is only applicable when costs are identical.
- d) Does not consider the effectiveness of interventions.
Answer: a) Cannot compare interventions with different types of outcomes (e.g., cannot directly compare an intervention that reduces blood pressure with one that prevents fractures, unless a common outcome is found).
10. In CMA, if two generic versions of the same drug are proven bioequivalent, the analysis would primarily focus on comparing their:
- a) Clinical efficacy rates.
- b) Adverse effect profiles.
- c) Acquisition costs and any associated dispensing or administration costs.
- d) Patient-reported quality of life.
Answer: c) Acquisition costs and any associated dispensing or administration costs.
11. When the effectiveness of two treatments is measured in “symptom-free days,” which type of pharmacoeconomic analysis is being conducted if costs are also considered?
- a) Cost-Minimization Analysis
- b) Cost-Benefit Analysis
- c) Cost-Effectiveness Analysis
- d) Cost-Utility Analysis
Answer: c) Cost-Effectiveness Analysis
12. The “cost-effectiveness plane” is a graphical tool used in CEA. An intervention that is more effective and less costly than the comparator would fall into which quadrant, indicating it is “dominant”?
- a) Upper-right (more costly, more effective)
- b) Upper-left (more costly, less effective)
- c) Lower-left (less costly, less effective)
- d) Lower-right (less costly, more effective)
Answer: d) Lower-right (less costly, more effective)
13. If a new drug is more effective but also much more expensive than the standard treatment, the ICER helps decision-makers determine if the additional benefit is:
- a) Statistically significant.
- b) Worth the additional cost, often by comparing the ICER to a willingness-to-pay threshold.
- c) Due to chance.
- d) The same for all patients.
Answer: b) Worth the additional cost, often by comparing the ICER to a willingness-to-pay threshold.
14. A major challenge in conducting a Cost-Minimization Analysis is:
- a) Valuing health outcomes in monetary terms.
- b) Measuring Quality-Adjusted Life Years accurately.
- c) Ensuring and adequately demonstrating that the outcomes of the compared interventions are truly equivalent.
- d) Calculating the ICER.
Answer: c) Ensuring and adequately demonstrating that the outcomes of the compared interventions are truly equivalent.
15. The “perspective” of a CMA or CEA (e.g., societal, payer) is important because it:
- a) Only affects the calculation of effectiveness.
- b) Dictates which costs are included in the analysis.
- c) Guarantees the result will favor the newer drug.
- d) Is only relevant for Cost-Benefit Analysis.
Answer: b) Dictates which costs are included in the analysis.
16. Which of the following outcome measures would NOT typically be used in a Cost-Effectiveness Analysis?
- a) Life-years gained.
- b) Number of strokes prevented.
- c) Monetary value of patient’s willingness to pay for a cure.
- d) Percentage reduction in A1c.
Answer: c) Monetary value of patient’s willingness to pay for a cure. (This is more characteristic of CBA).
17. If a pharmacoeconomic study compares two drugs and finds that Drug A costs $200 and cures 80% of patients, while Drug B costs $150 and cures 75% of patients, a CMA would be inappropriate because:
- a) The costs are different.
- b) The outcomes (cure rates) are different.
- c) Both drugs are too expensive.
- d) The drugs are from different manufacturers.
Answer: b) The outcomes (cure rates) are different.
18. The results of a CEA are typically used to:
- a) Set the exact price of a new drug.
- b) Inform resource allocation decisions, formulary placement, and clinical guideline development.
- c) Prove the clinical superiority of one drug over another without considering cost.
- d) Market drugs directly to consumers.
Answer: b) Inform resource allocation decisions, formulary placement, and clinical guideline development.
19. A “cost per case avoided” is a common outcome metric in which type of pharmacoeconomic analysis?
- a) Cost-Minimization Analysis
- b) Cost-Effectiveness Analysis
- c) Cost-Consequence Analysis
- d) Cost-of-Illness Study
Answer: b) Cost-Effectiveness Analysis
20. If a CMA is conducted comparing two therapeutically equivalent antidepressants, which costs would be relevant to include from a payer perspective?
- a) Only the patient’s copay.
- b) Drug acquisition cost, dispensing fees, and costs of treating common side effects if they differ.
- c) Lost productivity of the patient.
- d) The cost of pain and suffering.
Answer: b) Drug acquisition cost, dispensing fees, and costs of treating common side effects if they differ. (If side effects differ, outcomes are not truly equivalent, pushing towards CEA/CUA). Assuming side effects are equivalent for a true CMA.
Revised Question 20: 20. If a CMA is conducted comparing two therapeutically equivalent antidepressants with identical side effect profiles, which costs would be most relevant from a payer perspective?
- a) Only the patient’s copay.
- b) Drug acquisition cost and dispensing fees.
- c) Lost productivity of the patient.
- d) The cost of pain and suffering.
Answer: b) Drug acquisition cost and dispensing fees.
21. An ICER is considered “incremental” because it focuses on the:
- a) Total cost and total effect of only one intervention.
- b) Additional cost per additional unit of effect gained when moving from one intervention to another.
- c) Average cost-effectiveness of all available interventions.
- d) Initial cost of drug development.
Answer: b) Additional cost per additional unit of effect gained when moving from one intervention to another.
22. One reason why the results of a CMA might be questioned is if the evidence for “equivalent outcomes” comes from:
- a) Multiple large, well-conducted randomized controlled trials.
- b) A single, small, non-randomized observational study with potential biases.
- c) A systematic review and meta-analysis.
- d) FDA bioequivalence data for two generics.
Answer: b) A single, small, non-randomized observational study with potential biases.
23. In CEA, if an intervention is found to be “dominated,” it means it is:
- a) Less costly and more effective than the comparator.
- b) More costly and less effective than the comparator.
- c) Equally costly and equally effective.
- d) More costly but also more effective.
Answer: b) More costly and less effective than the comparator.
24. Which type of cost is often difficult to measure comprehensively but is ideally included in a CEA from a societal perspective?
- a) Drug acquisition costs
- b) Hospitalization costs
- c) Indirect costs (e.g., productivity losses)
- d) Laboratory test costs
Answer: c) Indirect costs (e.g., productivity losses)
25. The main output of a Cost-Minimization Analysis is typically:
- a) An ICER.
- b) A net benefit value.
- c) The difference in total costs between the alternatives.
- d) A QALY calculation.
Answer: c) The difference in total costs between the alternatives.
26. When applying discounting to costs and outcomes in a CEA that extends over several years, the discount rate used should ideally be:
- a) Different for costs and outcomes.
- b) The same for costs and outcomes, and clearly justified.
- c) Zero, as discounting is not important.
- d) Very high (e.g., 20%) to minimize future values.
Answer: b) The same for costs and outcomes, and clearly justified.
27. A common criticism of using “cost per life-year gained” as the primary outcome in CEA is that it:
- a) Is too difficult to calculate.
- b) Does not account for the quality of those life-years.
- c) Always favors more expensive treatments.
- d) Is only relevant for pediatric patients.
Answer: b) Does not account for the quality of those life-years. (This is why CUA/QALYs were developed).
28. If a pharmacoeconomic study uses a decision tree model, it’s important when critiquing to assess if:
- a) The tree has at least 10 branches.
- b) The probabilities at chance nodes are based on credible evidence and the pathways are clinically logical.
- c) The model only includes two possible outcomes.
- d) The tree diagram is hand-drawn.
Answer: b) The probabilities at chance nodes are based on credible evidence and the pathways are clinically logical.
29. A “league table” in pharmacoeconomics presents:
- a) A ranking of pharmaceutical companies by profit.
- b) A comparison of ICERs from various healthcare interventions, often to help with priority setting.
- c) A list of all available drugs for a specific condition.
- d) The costs of different diagnostic tests.
Answer: b) A comparison of ICERs from various healthcare interventions, often to help with priority setting.
30. The choice of time horizon in a CEA is critical. For a preventive intervention for a chronic disease, an appropriate time horizon would likely be:
- a) One year only.
- b) Long enough to capture all relevant long-term costs and health outcomes, potentially a lifetime horizon.
- c) The duration of the shortest clinical trial available.
- d) Six months.
Answer: b) Long enough to capture all relevant long-term costs and health outcomes, potentially a lifetime horizon.
31. If a CMA shows that Generic Drug X is $50 cheaper per treatment course than therapeutically equivalent Brand Drug Y, the conclusion is that:
- a) Brand Drug Y is more effective.
- b) Generic Drug X is the preferred option based on cost minimization.
- c) Both drugs are equally cost-effective.
- d) A CEA is needed to compare them.
Answer: b) Generic Drug X is the preferred option based on cost minimization.
32. When an ICER from a CEA is interpreted, a lower ICER generally indicates:
- a) Worse cost-effectiveness.
- b) Better cost-effectiveness (more health gain per dollar spent).
- c) Higher costs.
- d) Lower effectiveness.
Answer: b) Better cost-effectiveness (more health gain per dollar spent).
33. One-way sensitivity analysis in a CEA would involve changing:
- a) All input parameters simultaneously within their probability distributions.
- b) One input parameter (e.g., cost of drug, probability of an event) at a time across a range of plausible values to see its effect on the ICER.
- c) The type of pharmacoeconomic analysis.
- d) The perspective of the study.
Answer: b) One input parameter (e.g., cost of drug, probability of an event) at a time across a range of plausible values to see its effect on the ICER.
34. Which of the following questions is LEAST relevant when critiquing the methodology of a Cost-Effectiveness Analysis?
- a) Were the comparators appropriate?
- b) Were costs and outcomes measured accurately and valued credibly?
- c) Was the marketing budget for the new drug disclosed?
- d) Was discounting performed appropriately for studies with a long time horizon?
Answer: c) Was the marketing budget for the new drug disclosed?
35. If a Cost-Effectiveness Analysis is assessing a smoking cessation program, an appropriate measure of effectiveness might be:
- a) The cost of nicotine patches.
- b) The number of successful quitters or life-years gained due to quitting.
- c) Patient satisfaction with the program’s counselors.
- d) The monetary benefit of reduced healthcare costs due to fewer smoking-related illnesses. (This would be part of a CBA or societal CEA).
Answer: b) The number of successful quitters or life-years gained due to quitting.
36. A major assumption that must hold true for a Cost-Minimization Analysis to be valid is:
- a) The interventions have vastly different side effect profiles.
- b) The more expensive drug is always more effective.
- c) The health outcomes of the interventions being compared are truly identical or equivalent.
- d) All costs are paid by the patient out-of-pocket.
Answer: c) The health outcomes of the interventions being compared are truly identical or equivalent.
37. In CEA, if an ICER falls in the upper-left quadrant of the cost-effectiveness plane (more costly, less effective), the new intervention is:
- a) Dominant
- b) Dominated (clearly not cost-effective)
- c) Cost-effective if the ICER is below the WTP threshold.
- d) A trade-off requiring consideration of the WTP.
Answer: b) Dominated (clearly not cost-effective)
38. A key difference between the output of a CMA and a CEA is that CMA identifies the _______ option, while CEA provides a _______ of cost per unit of health gain.
- a) most effective; monetary benefit
- b) least costly; ratio
- c) most preferred by patients; utility score
- d) newest; safety profile
Answer: b) least costly; ratio
39. When critiquing a CMA, it’s important to verify that the evidence for equivalent outcomes is not based on:
- a) A well-conducted meta-analysis of head-to-head trials.
- b) Assuming equivalence based only on similar mechanisms of action without direct comparative clinical data.
- c) FDA approval for the same indication.
- d) Bioequivalence data for different formulations of the same drug.
Answer: b) Assuming equivalence based only on similar mechanisms of action without direct comparative clinical data.
40. Which of the following statements best describes how Cost-Effectiveness Analysis handles quality of life?
- a) It always measures quality of life in monetary terms.
- b) It measures outcomes in natural units (e.g., life years), which may not directly incorporate quality of life unless the outcome itself is a quality-of-life measure (e.g., symptom-free days). CUA is needed for QALYs.
- c) It ignores quality of life completely.
- d) It assumes quality of life is identical for all interventions.
Answer: b) It measures outcomes in natural units (e.g., life years), which may not directly incorporate quality of life unless the outcome itself is a quality-of-life measure (e.g., symptom-free days). CUA is needed for QALYs.
41. A research article titled “A Cost-Minimization Analysis of Two Statins for Primary Prevention of Cardiovascular Disease” would imply that the authors are assuming the two statins have:
- a) Different impacts on LDL cholesterol reduction.
- b) Equivalent efficacy and safety in preventing cardiovascular events in the study population.
- c) Different mechanisms of action.
- d) One is significantly more toxic.
Answer: b) Equivalent efficacy and safety in preventing cardiovascular events in the study population.
42. A common “natural health unit” used as an outcome in CEAs for cancer treatments is:
- a) Cost per QALY gained.
- b) Life-years gained (LYG) or progression-free survival (PFS) months.
- c) Patient satisfaction scores.
- d) Net monetary benefit.
Answer: b) Life-years gained (LYG) or progression-free survival (PFS) months.
43. When critiquing the comparators in a CEA, if the “standard care” comparator used in the study is no longer considered the best available standard care in current practice, this may limit the study’s:
- a) Internal validity.
- b) Relevance and applicability to current decision-making.
- c) Statistical power.
- d) Ability to measure costs.
Answer: b) Relevance and applicability to current decision-making.
44. If a CMA is used to compare two different brands of the same generic drug that have demonstrated bioequivalence, the main cost component of interest would be:
- a) Research and development costs.
- b) Drug acquisition cost.
- c) Cost of treating adverse effects (assuming these are truly identical).
- d) Intangible costs.
Answer: b) Drug acquisition cost.
45. The “threshold ICER” or willingness-to-pay (WTP) threshold is used in CEA to:
- a) Determine the sample size for clinical trials.
- b) Provide a benchmark against which the calculated ICER can be compared to judge whether an intervention offers acceptable value for money.
- c) Calculate the discount rate.
- d) Ensure all outcomes are equivalent.
Answer: b) Provide a benchmark against which the calculated ICER can be compared to judge whether an intervention offers acceptable value for money.
46. One limitation of using an ICER from a CEA is that it does not directly tell you:
- a) The additional cost for an additional unit of health gain.
- b) Whether the intervention is affordable within a specific budget (budget impact).
- c) How to conduct a sensitivity analysis.
- d) The perspective of the study.
Answer: b) Whether the intervention is affordable within a specific budget (budget impact).
47. When critiquing a CEA, if the study population is very different from the population to whom you might apply the results (e.g., study in young adults, applying to elderly), this impacts the:
- a) Type of costs included.
- b) Discount rate used.
- c) External validity or generalizability of the findings.
- d) Method of outcome measurement.
Answer: c) External validity or generalizability of the findings.
48. Both CMA and CEA require careful and transparent:
- a) Measurement of outcomes in QALYs.
- b) Identification, measurement, and valuation of all relevant costs from the chosen perspective.
- c) Calculation of a benefit-to-cost ratio.
- d) Monetization of all health benefits.
Answer: b) Identification, measurement, and valuation of all relevant costs from the chosen perspective.
49. If a new therapy is less effective and more expensive than the current standard, a CEA would show it is _______, and a CMA would be _______.
- a) dominant; appropriate
- b) dominated; inappropriate
- c) cost-effective; the best choice
- d) a good value; not needed
Answer: b) dominated; inappropriate
50. Pharmacists skilled in critiquing CMA and CEA studies can better contribute to:
- a) Only inventory management.
- b) Evidence-based formulary decisions, guideline development, and optimizing medication use for value.
- c) Marketing new drugs to physicians.
- d) Determining the exact cause of a patient’s illness.
Answer: b) Evidence-based formulary decisions, guideline development, and optimizing medication use for value.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com